Search

The composites of Mg20Pr1Sm3Y1Ni10 as-quenched alloy and 3 wt.% M (M = CoS, CoS2, MoS2) catalyst were prepared by high-speed vibration ball mill. The effects of metal sulfides on the hydrogenation and dehydrogenation dynamics of alloys were compared. The results show that the as-milled composites contain a large number of amorphous embedded by a small amount of nanocrystals, and there are many point defects. After ball milling, the crystal grain size in the composites containing CoS is relatively larger, followed by CoS2 and MoS2 again. After hydrogenation, the amorphous phase is crystallized to form Mg2NiH4, YH3, Pr8H18.96, Sm3H7, Mg, Co or Mo phases, however, Mg2Ni, YH2, PrH2 and Ni3Y phases appeared after dehydrogenation. The maximum hydrogenation capacity of the composites containing CoS, CoS2 and MoS2 are 3.939, 4.265 and 4.507 wt.%, respectively. The hydrogenation saturation ratio of composite containing MoS2 is higher than that of the composites containing CoS and CoS2. The dehydrogenation activation energy of the composites containing CoS, CoS2 and MoS2 is 107.76, 68.43 and 63.28 kJ.mol−1.H2. On the improvement of hydrogen storage performance of Mg20Pr1Sm3Y1Ni10 alloy, the catalytic effect of MoS2 sulfide is better than that of CoS2 sulfide, and which is better than CoS sulfide.

Background: The effectiveness of apatinib and cabozantinib for the treatment of radioactive iodine–refractory differentiated thyroid cancer (RAIR-DTC) has been demonstrated recently. We aimed to evaluate the cost-effectiveness of these treatments from the Chinese healthcare system perspective.Methods: Two partitioned survival models over a 10-year horizon were built to compare the cost and effectiveness of apatinib vs. placebo and cabozantinib vs. placebo based on the clinical data from the phase 3 randomized REALITY and COSMIC-311 trials. Costs and utility data were obtained from the literature and institutional database. The incremental cost-effectiveness ratio (ICER) was calculated. One-way and probabilistic sensitivity analysis was performed to test the robustness of the conclusion.Results: Apatinib yielded an additional quality-adjusted life-year (QALY) of 0.74 at an additional cost of Chinese Renminbi ¥44,077. The ICER was ¥93,460 (US dollar $13545)/QALY and it was below the current willingness-to-pay (WTP) threshold of ¥217341/QALY. Cabozantinib was associated with an additional QALY of 0.79 at an extra cost of ¥3,55,614 when compared with placebo, and the ICER was ¥4,52,325 ($65,554)/QALY, which was above the WTP threshold. The conclusion were robust under one-way and probabilistic sensitivity analysis. The price of cabozantinib has to drop to ¥5.87/mg (39% of the current price) for it has a 50% likelihood of being cost-effective.Conclusion: Apatinib is cost-effective for RAIR-DTC when compared with placebo from the perspective of Chinese healthcare system. However, based on the current evidence, cabozantinib might not be cost-effective and a reduction of price is warranted.